1-3 of 3
Klemens Scheidhauer, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Study of Myeloablative Anti-CD20+ Radioimmunotherapy with I-131-Rituximab in High-Risk CD20-Positive Non Hodgkin Lymphoma

Kathleen Schwarz, MD, Wagner Julia, MD, Susanne Schreiber, MD, Burkhard Schmidt, MD, Alexander Hoellein, MD, Mareike Verbeek, MD, Markus Schwaiger, MD, Christian Peschel, MD, Klemens Scheidhauer, MD, Christoph von Schilling, MD, Ulrich Keller, MD
Journal: Blood
Blood (2012) 120 (21): 3700.
https://doi.org/10.1182/blood.V120.21.3700.3700
Published: 2012
Journal Articles

MERIT Study – “Multicenter Evaluation of Patient- and Lesion-Specific Prognostic Factors for RadioImmunoTherapy with 90 yttrium-Labeled Anti-CD20 in Follicular Non-Hodgkin's lymphoma”.

Aleksandar Grgic, MD, Ursula Nestle, MD, PhD, Elena Ballek, MD, Klemens Scheidhauer, MD, PhD, Cornelia Puskas, MD, Jochem Koenig, PhD, Karin Hohloch, MD, Joerg Schubert, MD, Lorenz H. Truemper, Carl-Martin Kirsch, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 4792.
https://doi.org/10.1182/blood.V114.22.4792.4792
Published: 2009
Journal Articles

Y-90 Ibritumomab Tiuxetan as Consolidation Following Three Cycles of Fludarabine-Cyclophosphamide-Rituximab Chemoimmunotherapy in Patients with Relapsed Follicular, Indolent or Mantle-Cell Lymphoma: A Prospective “Dose”-Finding Study.

Christoph von Schilling, MD, Kathleen Schwarz, MD, Georg Hess, MD., Ph.D., Andreas Viardot, MD, Michael Sandherr, MD, Stefan Krause, MD., Ph.D., Jan P. Simon, MD, Ph.D., Nadine Roethling, Christian Peschel, MD, Ph.D., Markus Schwaiger, MD, Ph.D., Klemens Scheidhauer, MD, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 3426.
https://doi.org/10.1182/blood.V110.11.3426.3426
Published: 2007